Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres Gastrointestinal / Cáncer Gástrico / Recursos de NCI
National Cancer Institute®
Ultima Vez Modificado: 1 de junio del 2002
1
UI - 11911297
AU - Nilsson A; Janson ET; Eriksson B; Larsson A
TI -
Levels of angiogenic peptides in sera from patients with carcinoid
tumours during alpha-interferon treatment.
SO - Anticancer Res 2001 Nov-Dec;21(6A):4087-90
AD - Department of Medical Sciences, University Hospital, Uppsala, Sweden.
BACKGROUND: Alpha-interferon, a known inhibitor of angiogenesis and cell
proliferation, is used in the standard treatment of patients with
carcinoid tumors. We studied the levels of two angiogenic peptides (bFGF
and VEGF) in sera from patients with carcinoid tumours before and during
treatment with alpha-interferon. The aim was to investigate if the
antitumoral effect of alpha-interferon in these patients could be at
least in part explained by a reduction in the measured angiogenetic
peptides. PATIENTS AND METHODS: Sera from 29 patients with carcinoid
tumours were collected before and during alpha-interferon treatment and
analyzed using commercially available ELISA-kits. RESULTS: Interferon
alpha treatment did not cause reduction of bFGF and VEGF levels in serum
from patients with carcinoid tumours. In fact there was no correlation
between changes in bFGF or VEGF levels and treatment effect. CONCLUSION:
The action of alpha-interferon does not seem to be mediated by bFGF or
VEGF in patients with carcinoid tumours. If alpha-interferon has an
anti-angiogenic effect in this patient group, it is probably mediated by
angiogenic peptides other than bFGF and VEGF.
2
UI - 11862561
AU - Heah SM; Eu KW; Ooi BS; Ho YH; Seow-Choen F
TI -
Tumor size is irrelevant in predicting malignant potential of carcinoid
tumors of the rectum.
SO - Tech Coloproctol 2001 Aug;5(2):73-7
AD - Department of Colorectal Surgery, Singapore General Hospital, Outram
Road, 169608 Singapore.
The malignant potential and prognosis of rectal carcinoids are said to
be related to tumor size. Our study assessed if size could predict the
malignant potential and hence its management. All patients in the
Department of Colorectal Surgery, Singapore General Hospital, who
years (range, 33-77 years) were studied. Median follow-up was 40 months
(range, 5-120 months). The median tumor diameter was 2.5 cm (range,
0.1-5.0 cm). Eleven patients underwent radical resection and 9 patients
had local resection for a presumed benign tumor. Morbidity was 15% and
postoperative death was 5%. Overall median survival was 24 months
(range, 5-120 months). One patient had an anterior resection for rectal
adenocarcinoma but had an incidental 0.1-cm carcinoid tumor near the
resection margin which on histology was found to have carcinoid tumor
metastasis to 2 out of 12 lymph nodes. In conclusion, tumor size cannot
predict malignant potential as even small tumors (<1 cm) can be
malignant. Accurate preoperative staging with radical surgery may be
required.
3
UI - 12059131
AU - Kasi VS; Ahsanudin AN; Gilbert C; Orr L; Moran J; Sorrell VL
TI -
Isolated metastatic myocardial carcinoid tumor in a 48-year-old man.
SO - Mayo Clin Proc 2002 Jun;77(6):591-4
AD - Division of Cardiology, Pitt County Memorial Hospital and East Carolina
University, Greenville, NC 27858, USA.
This brief report describes an asymptomatic patient with a myocardial
mass. Two-dimensional echocardiography, technetium Tc 99m cardiac
nuclear scan, and transesophageal echocardiography were performed to
define the mass. The mass, which involved the subvalvar right
ventricular free wall, was resected and determined to be a metastatic
carcinoid tumor by histologic and immunohistochemical analysis. Further
investigation revealed the presence of a midgut carcinoid tumor located
within the terminal ileum, which was also resected surgically. The
patient recovered well after surgery and adjunctive chemotherapy. To our
knowledge, this is the first report of comprehensive nuclear and
echocardiographic imaging, supplemented by surgical and pathologic
findings, in an asymptomatic patient with isolated myocardial metastasis
of an ileal carcinoid tumor.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
What every person should know about screening, learning about your disease and the importance of cllinical research. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

